
RATES OF > 50% CHANGE FROM BASELINE IN PAIN-VAS
PROPORTION OF PATIENTS
100%
75%
50%
25%
0%
14% (1/7)
29% (2/7)
25% (1/4)
50% (6/12)
67% (8/12)
67% (4/6)
55% (6/11)
80% (4/5)
23% (3/13)
46% (6/13)
50% (4/8)
ANTIBODY A 18 mg
ANTIBODY A 90 mg
ANTIBODY A 180 mg
USTEKINUMAB
4 WEEKS
12 WEEKS
24 WEEKS (INCOMPLETE FOLLOW UP)

FIG. 1

FIG. 2


PROPORTION OF PATIENTS ACHIEVING PASI 50 (%)
100
90
80
70
60
50
40
30
20
10
0
DOSE*
4
8
12
16
20
24
WEEK
DOSE
100%
95%
93%
87%
BI 18 mg
BI 90 mg
BI 180 mg
USTEKINUMAB
*18 mg ANTIBODY A ONLY GIVEN ONCE AT WEEK 0.
WEEKS 0–16, n~40; WEEK 20, n~35; WEEK 24, n~25.

FIG. 3


PROPORTION OF PATIENTS ACHIEVING PASI 75 (%)
100
90
80
70
60
50
40
30
20
10
0
98%
90%
76%
68%
DOSE*
4
8
12
16
20
24
WEEK
DOSE
DOSE
BI 18 mg
BI 90 mg
BI 180 mg
USTEKINUMAB
*18 mg ANTIBODY A ONLY GIVEN ONCE AT WEEK 0.
WEEKS 0–16, n~40; WEEK 20, n~35; WEEK 24, n~25.

FIG. 4


PROPORTION OF PATIENTS ACHIEVING PASI 90 (%)
100
90
80
70
60
50
40
30
20
10
0
80%
73%
42%
33%
DOSE*
0
2
4
DOSE
6
8
WEEK
12
16
DOSE
20
24
BI 18 mg
BI 90 mg
BI 180 mg
USTEKINUMAB
*18 mg ANTIBODY A ONLY GIVEN ONCE AT WEEK 0.
WEEKS 0–16, n~40; WEEK 20, n~35; WEEK 24, n~25.

FIG. 5


PROPORTION OF PATIENTS ACHIEVING PASI 100 (%)
100
90
80
70
60
50
40
30
20
10
0
DOSE*
0
2
4
6
8
12
16
20
24
WEEK
DOSE
49%
41%
18%
15%
BI 18 mg
BI 90 mg
BI 180 mg
USTEKINUMAB
*18 mg ANTIBODY A ONLY GIVEN ONCE AT WEEK 0.
WEEKS 0–16, n~40;WEEK 20, n~35;WEEK 24, n~25.